HRS-3738 vs Pomalidomide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Cereblon (CRBN) · full Multiple Myeloma pipeline

HRS-3738

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 1 in Multiple Myelomasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05363800 (registry estimate)

No aligned efficacy figure on record for this race.

Pomalidomide

Marketed by Bristol-Myers Squibb and partners

Approved in Multiple Myelomasmall molecule (IMiD / cereblon modulator)
Partial signal

NCT01311687 · Phase 3 · completed

This was a large, randomized 2:1 active-controlled trial involving 302 participants assigned to pomalidomide plus low-dose dexamethasone and 153 assigned to high-dose dexamethasone, but treatment was open-label rather than double-blinded. The hard clinical primary endpoint, progression-free survival, was met: median PFS was 15.7 versus 8.0 weeks, with HR 0.45 (95% CI 0.35–0.59; p<0.001), supporting a moderate evidence grade.

Next expected readout: November 2026 · NCT04973605 (registry estimate)

Reported efficacy

Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23% (not_applicable)

Result source: NCT01324947

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHRS-3738Pomalidomide
PFS, median—Not reported3.6 vs 1.9vs Dexamethasonen 302NCT01311687
31 other results
OS, median—Not reported12.5 vs 8.1vs Dexamethasonen 302NCT01311687
13 other results
ORR—Not reported23%bn 74NCT01324947
17 other results
  • 23.5% vs 3.9% n 302 · Phase 3 · secondary NCT01311687
  • 22.2% vs 3.3% n 302 · Phase 3 · secondary NCT01311687
  • 60.4% vs 35.3% n 154 · Phase 3 · secondary NCT02990338
  • 48% vs 54.9% n 75 · Phase 3 · secondary NCT02726581
  • 33.4% n 682 · Phase 3 · secondary NCT01712789
  • 20.3% n 74 · Phase 3 · secondary NCT01324947
  • 20% 4 mg/d on 21 Days/28 Day Cycle · wk 8 · n 20 · Phase 2 · primary NCT01319422
  • 15.8% 2 mg/d on 28 Days/28 Day Cycle · wk 8 · n 19 · Phase 2 · primary NCT01319422
  • 83% 300 mg · n 6 · Phase 1/2 · secondary NCT03439280
  • 87.5% IR 250 mg/day · n 8 · Phase 1 · secondary NCT02939183
  • 60% IR 225 mg/day · n 10 · Phase 1 · secondary NCT02939183
  • 85.7% IR 200 mg/day · n 7 · Phase 1 · secondary NCT02939183
  • 60% GR 200 mg/day · n 5 · Phase 1 · secondary NCT02939183
  • 0% GR 150 mg/day · n 3 · Phase 1 · secondary NCT02939183
  • 50% 2.5 mg/kg + Pom/Dex · n 4 · Phase 1 · secondary NCT03828292
  • 77.8% n 9 · Phase 1 · secondary NCT03269136
  • 33.3% IR 150 mg/day · n 3 · Phase 1 · secondary NCT02939183
VGPR or better—Not reported31.8% vs 8.5%vs Pomalidomide + Dexamethasonen 154NCT02990338
MRD negativity—Not reported—Not posted · NCT03651128

PFS, median

HRS-3738
—Not reported
Pomalidomide
3.6 vs 1.9vs Dexamethasonen 302NCT01311687
31 other results

OS, median

HRS-3738
—Not reported
Pomalidomide
12.5 vs 8.1vs Dexamethasonen 302NCT01311687
13 other results

ORR

HRS-3738
—Not reported
Pomalidomide
23%bn 74NCT01324947
17 other results
  • 23.5% vs 3.9% n 302 · Phase 3 · secondary NCT01311687
  • 22.2% vs 3.3% n 302 · Phase 3 · secondary NCT01311687
  • 60.4% vs 35.3% n 154 · Phase 3 · secondary NCT02990338
  • 48% vs 54.9% n 75 · Phase 3 · secondary NCT02726581
  • 33.4% n 682 · Phase 3 · secondary NCT01712789
  • 20.3% n 74 · Phase 3 · secondary NCT01324947
  • 20% 4 mg/d on 21 Days/28 Day Cycle · wk 8 · n 20 · Phase 2 · primary NCT01319422
  • 15.8% 2 mg/d on 28 Days/28 Day Cycle · wk 8 · n 19 · Phase 2 · primary NCT01319422
  • 83% 300 mg · n 6 · Phase 1/2 · secondary NCT03439280
  • 87.5% IR 250 mg/day · n 8 · Phase 1 · secondary NCT02939183
  • 60% IR 225 mg/day · n 10 · Phase 1 · secondary NCT02939183
  • 85.7% IR 200 mg/day · n 7 · Phase 1 · secondary NCT02939183
  • 60% GR 200 mg/day · n 5 · Phase 1 · secondary NCT02939183
  • 0% GR 150 mg/day · n 3 · Phase 1 · secondary NCT02939183
  • 50% 2.5 mg/kg + Pom/Dex · n 4 · Phase 1 · secondary NCT03828292
  • 77.8% n 9 · Phase 1 · secondary NCT03269136
  • 33.3% IR 150 mg/day · n 3 · Phase 1 · secondary NCT02939183

VGPR or better

HRS-3738
—Not reported
Pomalidomide
31.8% vs 8.5%vs Pomalidomide + Dexamethasonen 154NCT02990338

MRD negativity

HRS-3738
—Not reported
Pomalidomide
—Not posted · NCT03651128
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-3738: no structured comparison results are available for Multiple Myeloma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HRS-3738: 0 of 4 rows · Pomalidomide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPomalidomide
Dropout rate
0%a
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3
show 54 more results
n/a: no completion milestone
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
64.3%4 mg
NCT00833833 · Phase 1/2
60%5 mg
NCT00833833 · Phase 1/2
62.5%3 mg
NCT00833833 · Phase 1/2
66.7%2 mg
NCT00833833 · Phase 1/2
—Phase 2: Pomalidomide
NCT00833833 · Phase 1/2
—Phase 2: Pomalidomide (Pom + Dex O
NCT00833833 · Phase 1/2 · combination
—Phase 2: Pomalidomide (Pom Only)
NCT00833833 · Phase 1/2
—Phase 2: Pomalidomide + Dexamethas
NCT00833833 · Phase 1/2 · combination
—Daratumumab (IV)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
—Daratumumab (SC)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
1.1%Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
4%Arm A: N-Pd
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
—Arm B: NE-Pd Crossover
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
0%Arm C: NE-Pd
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT01712789 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02654132 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneEN Cohort
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneEPd Cohort
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
14.3%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
34.3%High Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
20.6%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
72.7%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
38.3%High Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
35%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
43.3%High Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT02011113 · Phase 2 · registry result, not featured evidence · combination
0%4 mg/d on 21 Days/28 Day Cycle
NCT01319422 · Phase 2 · registry result, not featured evidence
5%2 mg/d on 28 Days/28 Day Cycle
NCT01319422 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT01177735 · Phase 2 · registry result, not featured evidence
—Nivolumab + Daratumumab Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
83.3%Nivolumab + Daratumumab_Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
85.7%Nivolumab + Daratumumab_Cohort A2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
83.7%Nivolumab + Daratumumab_Cohort B1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
72.7%Nivolumab + Daratumumab_Cohort B2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
38.5%Nivolumab + Ipilimumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
100%Nivolumab + Lirilumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
99%Nivolumab Monotherapy (Expansion)
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%300 mg
NCT03439280 · Phase 1/2 · registry result, not featured evidence · combination · Multiple Myeloma · phase 1/2
0%Part B: MOR03087 Weekly Dose Escal
NCT01421186 · Phase 1/2 · registry result, not featured evidence
0%Part C: MOR03087 Plus Dexamethason
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
0%Part D: MOR03087 Plus Pomalidomide
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
0%Part E: MOR03087 Plus Lenalidomide
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
37.5%IR 250 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
63.6%IR 225 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
40%GR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
22.2%IR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
60%GR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
33.3%IR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3
show 54 more results
9.5%
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
14.3%4 mg
NCT00833833 · Phase 1/2
10%5 mg
NCT00833833 · Phase 1/2
0%3 mg
NCT00833833 · Phase 1/2
16.7%2 mg
NCT00833833 · Phase 1/2
—Phase 2: Pomalidomide
NCT00833833 · Phase 1/2
—Phase 2: Pomalidomide (Pom + Dex O
NCT00833833 · Phase 1/2 · combination
—Phase 2: Pomalidomide (Pom Only)
NCT00833833 · Phase 1/2
—Phase 2: Pomalidomide + Dexamethas
NCT00833833 · Phase 1/2 · combination
—Daratumumab (IV)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
—Daratumumab (SC)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
14.3%
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
—Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
—Arm A: N-Pd
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
—Arm B: NE-Pd Crossover
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
—Arm C: NE-Pd
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
7.6%
NCT01712789 · Phase 3 · registry result, not featured evidence · combination
—
NCT02654132 · Phase 2 · registry result, not featured evidence · combination
0%EN Cohort
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
7.4%EPd Cohort
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
2.9%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
8.6%High Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
2.9%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
9.1%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
6.7%High Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
1.7%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
8.3%High Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
11.1%
NCT02011113 · Phase 2 · registry result, not featured evidence · combination
—4 mg/d on 21 Days/28 Day Cycle
NCT01319422 · Phase 2 · registry result, not featured evidence
—2 mg/d on 28 Days/28 Day Cycle
NCT01319422 · Phase 2 · registry result, not featured evidence
—
NCT01177735 · Phase 2 · registry result, not featured evidence
—Nivolumab + Daratumumab Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort A2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort B1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort B2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Ipilimumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Lirilumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab Monotherapy (Expansion)
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
—300 mg
NCT03439280 · Phase 1/2 · registry result, not featured evidence · combination · Multiple Myeloma · phase 1/2
—Part B: MOR03087 Weekly Dose Escal
NCT01421186 · Phase 1/2 · registry result, not featured evidence
—Part C: MOR03087 Plus Dexamethason
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
—Part D: MOR03087 Plus Pomalidomide
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
—Part E: MOR03087 Plus Lenalidomide
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
11.1%
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
0%IR 250 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
9.1%IR 225 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
0%GR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
0%IR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
20%GR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
0%IR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
65%a
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3
show 54 more results
71.2%
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
57.1%4 mg
NCT00833833 · Phase 1/2
40%5 mg
NCT00833833 · Phase 1/2
50%3 mg
NCT00833833 · Phase 1/2
50%2 mg
NCT00833833 · Phase 1/2
—Phase 2: Pomalidomide
NCT00833833 · Phase 1/2
47.5%Phase 2: Pomalidomide (Pom + Dex O
NCT00833833 · Phase 1/2 · combination
46.7%Phase 2: Pomalidomide (Pom Only)
NCT00833833 · Phase 1/2
61.6%Phase 2: Pomalidomide + Dexamethas
NCT00833833 · Phase 1/2 · combination
42.9%Daratumumab (IV)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
54.2%Daratumumab (SC)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
73.7%
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
63.7%Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
—Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
72.2%Arm A: N-Pd
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
62.5%Arm B: NE-Pd Crossover
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
75%Arm C: NE-Pd
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
66.3%
NCT01712789 · Phase 3 · registry result, not featured evidence · combination
70%
NCT02654132 · Phase 2 · registry result, not featured evidence · combination
50%EN Cohort
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
57.4%EPd Cohort
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
42.9%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
31.4%High Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
32.4%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
54.5%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
35%High Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
36.7%Low Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
26.9%High Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
44.4%
NCT02011113 · Phase 2 · registry result, not featured evidence · combination
55%4 mg/d on 21 Days/28 Day Cycle
NCT01319422 · Phase 2 · registry result, not featured evidence
36.8%2 mg/d on 28 Days/28 Day Cycle
NCT01319422 · Phase 2 · registry result, not featured evidence
8.5%
NCT01177735 · Phase 2 · registry result, not featured evidence
50%Nivolumab + Daratumumab Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
100%Nivolumab + Daratumumab_Cohort A2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
36.6%Nivolumab + Daratumumab_Cohort B1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
40.9%Nivolumab + Daratumumab_Cohort B2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
60%Nivolumab + Ipilimumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
47.2%Nivolumab + Lirilumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
47.6%Nivolumab Monotherapy (Expansion)
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
33.3%300 mg
NCT03439280 · Phase 1/2 · registry result, not featured evidence · combination · Multiple Myeloma · phase 1/2
100%Part B: MOR03087 Weekly Dose Escal
NCT01421186 · Phase 1/2 · registry result, not featured evidence
38.9%Part C: MOR03087 Plus Dexamethason
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
95.2%Part D: MOR03087 Plus Pomalidomide
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
82.4%Part E: MOR03087 Plus Lenalidomide
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
25%2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
0%2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
88.9%
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
50%IR 250 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
30%IR 225 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
100%GR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
75%IR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
100%GR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
50%IR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
anaemia 53%
neutropenia 51.7%
fatigue 34.3%
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3
show 51 more results
anaemia 49.3%
neutropenia 47.9%
constipation 21.9%
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
4 mg
fatigue 64.3%
neutropenia 57.1%
cough 50%
NCT00833833 · Phase 1/2
5 mg
neutropenia 90%
fatigue 70%
nausea 50%
NCT00833833 · Phase 1/2
3 mg
dyspnoea 75%
fatigue 62.5%
neutropenia 62.5%
NCT00833833 · Phase 1/2
2 mg
anaemia 83.3%
fatigue 66.7%
asthenia 50%
NCT00833833 · Phase 1/2
diarrhoea 27.9%
neutropenia 27.9%
anaemia 18%
NCT00833833 · Phase 1/2 · combination
neutropenia 49.5%
fatigue 43%
anaemia 33.6%
NCT00833833 · Phase 1/2
fatigue 55.4%
neutropenia 46.4%
anaemia 38.4%
NCT00833833 · Phase 1/2 · combination
fatigue 57.1%
neutropenia 57.1%
lymphopenia 42.9%
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
neutropenia 72.5%
anaemia 38.7%
thrombocytopenia 33.8%
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
neutropenia 50.7%
upper respiratory tract infection 34.9%
infusion related reaction 34.2%
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
neutropenia 54%
peripheral sensory neuropathy 48.2%
thrombocytopenia 39.6%
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
fatigue 47.2%
anaemia 36.1%
neutropenia 33.3%
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
fatigue 75%
anaemia 25%
asthenia 25%
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
pyrexia 58.3%
anaemia 45.8%
fatigue 41.7%
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
neutropenia 56.5%
anaemia 48.4%
thrombocytopenia 34.9%
NCT01712789 · Phase 3 · registry result, not featured evidence · combination
anaemia 28.3%
neutropenia 26.7%
diarrhoea 25%
NCT02654132 · Phase 2 · registry result, not featured evidence · combination
anaemia 33.3%
decreased appetite 33.3%
infusion related reaction 33.3%
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
fatigue 54.4%
upper respiratory tract infection 36.8%
diarrhoea 35.3%
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
Low Dose
hemoglobin decreased 97.1%
fatigue 88.6%
platelet count decreased 85.7%
NCT00558896 · Phase 2 · registry result, not featured evidence
High Dose
hemoglobin decreased 97.1%
fatigue 91.4%
leukocyte count decreased 88.6%
NCT00558896 · Phase 2 · registry result, not featured evidence
Low Dose
hemoglobin decreased 100%
fatigue 94.1%
leukocyte count decreased 79.4%
NCT00558896 · Phase 2 · registry result, not featured evidence
Low Dose
fatigue 97%
hemoglobin decreased 93.9%
peripheral sensory neuropathy 87.9%
NCT00558896 · Phase 2 · registry result, not featured evidence
High Dose
fatigue 93.3%
hemoglobin decreased 91.7%
leukocyte count decreased 90%
NCT00558896 · Phase 2 · registry result, not featured evidence
Low Dose
hemoglobin decreased 95%
fatigue 93.3%
neutrophil count decreased 80%
NCT00558896 · Phase 2 · registry result, not featured evidence
High Dose
hemoglobin decreased 96.6%
fatigue 93.3%
leukocyte count decreased 86.6%
NCT00558896 · Phase 2 · registry result, not featured evidence
neutropenia 72.2%
anaemia 47.2%
thrombocytopenia 44.4%
NCT02011113 · Phase 2 · registry result, not featured evidence · combination
4 mg/d on 21 Days/28 Day Cycle
leukopenia 75%
fatigue 60%
anemia 50%
NCT01319422 · Phase 2 · registry result, not featured evidence
2 mg/d on 28 Days/28 Day Cycle
fatigue 78.9%
leukopenia 63.2%
anemia 31.6%
NCT01319422 · Phase 2 · registry result, not featured evidence
anemia 100%
blood/bone marrow 100%
leukopenia 100%
NCT01177735 · Phase 2 · registry result, not featured evidence
anaemia 50%
arthralgia 50%
cough 50%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 80%
diarrhoea 80%
hypomagnesaemia 80%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 24.4%
infusion related reaction 24.4%
neutropenia 22%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 18.2%
diarrhoea 18.2%
infusion related reaction 18.2%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 46.2%
pyrexia 38.5%
cough 33.8%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 41.7%
diarrhoea 29.2%
anaemia 25%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 43.8%
cough 27.6%
diarrhoea 26.7%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
300 mg
neutropenia 50%
neutrophil count decreased 50%
constipation 33.3%
NCT03439280 · Phase 1/2 · registry result, not featured evidence · combination · Multiple Myeloma · phase 1/2
leukopenia 100%
neutropenia 75%
cough 50%
NCT01421186 · Phase 1/2 · registry result, not featured evidence
plasma cell myeloma 66.7%
nasopharyngitis 50%
leukopenia 44.4%
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
neutropenia 90.5%
leukopenia 81%
lymphopenia 66.7%
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
leukopenia 88.2%
lymphopenia 76.5%
neutropenia 70.6%
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + Pom/Dex
constipation 50%
neutrophil count decreased 50%
oedema peripheral 50%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Pom/Dex
abdominal pain upper 0%
abnormal faeces 0%
alanine aminotransferase increased 0%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
fatigue 77.8%
neutropenia 77.8%
diarrhoea 66.7%
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
IR 250 mg/day
diarrhoea 100%
nausea 100%
vomiting 87.5%
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
IR 225 mg/day
diarrhoea 80%
nausea 80%
vomiting 70%
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
GR 200 mg/day
diarrhoea 80%
back pain 60%
constipation 60%
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
IR 200 mg/day
nausea 75%
vomiting 75%
diarrhoea 62.5%
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
GR 150 mg/day
fatigue 75%
nausea 75%
cough 50%
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
IR 150 mg/day
anaemia 75%
diarrhoea 75%
nausea 75%
NCT02939183 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 51 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pomalidomide

PFS 3.62 vs 1.85 Dexamethasone months
time to event · months
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 15.7 weeks as posted
show 6 more results
3.69 vs 1.87 Dexamethasone months*
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 16 weeks as posted
11.53 vs 6.47 Pomalidomide + Dexamethasone months
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
7.491 vs 3.745 Pomalidomide + Dexamethasone months
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
11.2 vs 7.1 BTZ+LD-DEX months
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
8.38 vs 7.33 Pd months
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
10.25 vs 4.7 Pd months
NCT02654132 · Phase 2 · registry result, not featured evidence · combination
Overall Survival NA vs 7.85 Dexamethasone months
time to event · months
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3
show 6 more results
12.46 vs 8.05 Dexamethasone months*
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 54 weeks as posted
12.95 vs 8.15 Dexamethasone months*
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 56.1 weeks as posted
24.57 vs 17.71 Pomalidomide + Dexamethasone months
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
35.58 vs 31.61 BTZ+LD-DEX months
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
24.87 vs 21.39 Pd months
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
29.8 vs 17.41 Pd months
NCT02654132 · Phase 2 · registry result, not featured evidence · combination
ORR 23.5% (n=302) vs 3.9% (n=153) Dexamethasone
responder rate · % of participants
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3
show 3 more results
22.2% (n=302) vs 3.3% (n=153) Dexamethasone
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3
60.4% (n=154) vs 35.3% (n=153) Pomalidomide + Dexamethasone
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
48% (n=75) vs 54.9% (n=71) Pd
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
Time to Progression 4.62 vs 2.08 Dexamethasone months
time to event · months
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 20 weeks as posted
show 1 more result
12.71 vs 7.75 Pomalidomide + Dexamethasone months
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
Time to Response 1.87 vs 2.42 Dexamethasone months
time to event · months
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 8.1 weeks as posted
show 2 more results
1.94 vs 3.02 Pomalidomide + Dexamethasone months
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
5.91 vs 4.37 Pd months
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 8.1 vs 6.48 Dexamethasone months
time to event · months
NCT01311687 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 35.1 weeks as posted
show 3 more results
13.27 vs 11.07 Pomalidomide + Dexamethasone months
NCT02990338 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
13.7 vs 10.94 BTZ+LD-DEX months
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
8.51 vs 6.47 Pd months
NCT02726581 · Phase 3 · registry result, not featured evidence · combination
ORR 20% (n=20) @ 8wk4 mg/d on 21 Days/28 Day Cycle
responder rate · % of participants
No placebo or comparator arm
NCT01319422 · Phase 2 · registry result, not featured evidence
show 13 more results
83% (n=6)300 mg
NCT03439280 · Phase 1/2 · registry result, not featured evidence · combination · Multiple Myeloma · phase 1/2
87.5% (n=8)IR 250 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
60% (n=10)IR 225 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
85.7% (n=7)IR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
60% (n=5)GR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
33.3% (n=3)IR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
0% (n=3)GR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
50% (n=4)2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
15.8% (n=19) @ 8wk2 mg/d on 28 Days/28 Day Cycle
NCT01319422 · Phase 2 · registry result, not featured evidence
23% (n=74)
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
20.3% (n=74)
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
33.4% (n=682)
NCT01712789 · Phase 3 · registry result, not featured evidence · combination
77.8% (n=9)
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
PFS NA monthsIR 250 mg/day
time to event · months
No placebo or comparator arm
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
show 28 more results
17.5 monthsIR 225 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
NA monthsIR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
NA monthsGR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
14.24 monthsIR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
NA monthsGR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
3.69 months*
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to months from 16 weeks as posted
3.83 months*
NCT00833833 · Phase 1/2 · combination · converted to months from 16.6 weeks as posted
2.47 months*
NCT00833833 · Phase 1/2 · converted to months from 10.7 weeks as posted
4.6 months
NCT01712789 · Phase 3 · registry result, not featured evidence · combination
11.1 months
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
1.9 months
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
13 monthsLow Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
5 monthsLow Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
6.4 monthsLow Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
3.3 monthsHigh Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
7.7 monthsHigh Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
4.3 monthsHigh Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
14.1 monthsLow Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
4.38 months*
NCT02011113 · Phase 2 · registry result, not featured evidence · combination · converted to months from 19 weeks as posted
7.41 months*
NCT02011113 · Phase 2 · registry result, not featured evidence · combination · converted to months from 32.1 weeks as posted
6.24 months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
6.93 months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
3.02 months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
2.1 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence
8.4 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
15.9 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
26.7 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
6.7 months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
Time to Progression 4.38 months
time to event · months
No placebo or comparator arm
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to months from 19 weeks as posted
show 5 more results
4.8 months
NCT01712789 · Phase 3 · registry result, not featured evidence · combination
2.1 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence
8.4 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
15.9 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
33.2 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response NA monthsIR 250 mg/day
time to event · months
No placebo or comparator arm
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
show 24 more results
16.6 monthsIR 225 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
NA monthsIR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
NA monthsGR 200 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
NA monthsIR 150 mg/day
NCT02939183 · Phase 1 · registry result, not featured evidence · combination
6.53 months*
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to months from 28.3 weeks as posted
7.41 months*
NCT00833833 · Phase 1/2 · combination · converted to months from 32.1 weeks as posted
NA months
NCT00833833 · Phase 1/2
7.9 months
NCT01712789 · Phase 3 · registry result, not featured evidence · combination
21.3 monthsLow Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
8.2 monthsLow Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
15.6 monthsLow Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
3.1 monthsHigh Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
NA monthsHigh Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
8.3 monthsHigh Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
19 monthsLow Dose
NCT00558896 · Phase 2 · registry result, not featured evidence
NA months
NCT02011113 · Phase 2 · registry result, not featured evidence · combination
22.83 months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
24.84 months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
19.38 months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
NA months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
21.2 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
32.2 months
NCT01421186 · Phase 1/2 · registry result, not featured evidence · combination
8.3 months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
Overall Survival 7.75 months
time to event · months
No placebo or comparator arm
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to months from 33.6 weeks as posted
show 9 more results
14.45 months*
NCT00833833 · Phase 1/2 · combination · converted to months from 62.6 weeks as posted
13.68 months*
NCT00833833 · Phase 1/2 · converted to months from 59.3 weeks as posted
11.9 months
NCT01712789 · Phase 3 · registry result, not featured evidence · combination
41.2 months
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02612779 · Phase 2 · registry result, not featured evidence · combination
52.57 months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
30.39 months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
14.95 months
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
NA months
NCT03269136 · Phase 1 · registry result, not featured evidence · combination
Time to Response 1.92 months
time to event · months
No placebo or comparator arm
NCT01324947 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to months from 8.3 weeks as posted
show 6 more results
1.87 months*
NCT00833833 · Phase 1/2 · combination · converted to months from 8.1 weeks as posted
2.05 months*
NCT00833833 · Phase 1/2 · converted to months from 8.9 weeks as posted
1.87 months*
NCT01712789 · Phase 3 · registry result, not featured evidence · combination · converted to months from 8.1 weeks as posted
0.95 months*
NCT02011113 · Phase 2 · registry result, not featured evidence · combination · converted to months from 4.1 weeks as posted
1.87 months*
NCT02011113 · Phase 2 · registry result, not featured evidence · combination · converted to months from 8.1 weeks as posted
1.64 months*
NCT03269136 · Phase 1 · registry result, not featured evidence · combination · converted to months from 50 days as posted

+ 31 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-3738's landscape · Pomalidomide's landscape